Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor
- PMID: 12502502
- DOI: 10.2337/diabetes.52.1.124
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor
Abstract
We previously provided evidence that glucagon-like peptide 1 (GLP-1) induces pancreatic beta-cell growth nonadditively with glucose in a phosphatidylinositol (PI) 3-kinase- and protein kinase C zeta-dependent manner. However, the exact mechanism by which the GLP-1 receptor (GLP-1R), a member of the G protein-coupled receptor (GPCR) superfamily, activates the PI 3-kinase signaling pathway to promote beta-cell growth remains unknown. We hypothesized that the GLP-1R could activate PI 3-kinase and promote beta-cell proliferation through transactivation of the epidermal growth factor (EGF) receptor (EGFR), an event possibly linked to GPCRs via activation of c-Src and the production of putative endogenous EGF-like ligands. Both the c-Src inhibitor PP1 and the EGFR-specific inhibitor AG1478 blocked GLP-1-induced [(3)H]thymidine incorporation in INS(832/13) cells as well as in isolated rat islets, while only AG1478 inhibited the proliferative action of betacellulin (BTC), an EGFR agonist. Both compounds also suppressed GLP-1-induced PI 3-kinase activation. A time-dependent increase in tyrosine phosphorylation of the EGFR in response to GLP-1 was observed in INS(832/13) cells. This transactivation of the EGFR was sensitive to both the pharmacological agents PP1 and AG1478. The action of GLP-1 and BTC on INS cell proliferation was found to be not additive. Overexpression of a dominant-negative EGFR in INS cells with a retroviral expression vector curtailed GLP-1-induced beta-cell proliferation. GLP-1 treatment of INS cells caused a decrease in cell surface-associated BTC, as shown by FACS analysis. Also, the metalloproteinase inhibitor GM6001 and an anti-BTC neutralizing antibody suppressed the GLP-1 proliferative effect. Finally, coculturing the prostatic cancer cell line LNCaP that lacks GLP-1 responsiveness with INS cells increased LNCaP cell proliferation in the presence of GLP-1, thus revealing that INS cells secrete a growth factor in response to GLP-1. GM6001 and an anti-BTC neutralizing antibody suppressed increased LNCaP cell proliferation in the presence of GLP-1 in the coculture experiments. The results are consistent with a model in which GLP-1 increases PI 3-kinase activity and enhances beta-cell proliferation via transactivation of the EGFR that would require the proteolytic processing of membrane-anchored BTC or other EGF-like ligands.
Similar articles
-
Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.Diabetes. 2001 Oct;50(10):2237-43. doi: 10.2337/diabetes.50.10.2237. Diabetes. 2001. PMID: 11574404
-
Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells.Diabetologia. 1999 Jul;42(7):856-64. doi: 10.1007/s001250051238. Diabetologia. 1999. PMID: 10440129
-
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.J Biol Chem. 2003 Dec 26;278(52):52446-53. doi: 10.1074/jbc.M307612200. Epub 2003 Oct 16. J Biol Chem. 2003. PMID: 14565957
-
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.Mol Endocrinol. 2003 Feb;17(2):161-71. doi: 10.1210/me.2002-0306. Mol Endocrinol. 2003. PMID: 12554744 Review.
-
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.Endocrinology. 2004 Jun;145(6):2653-9. doi: 10.1210/en.2004-0015. Epub 2004 Mar 24. Endocrinology. 2004. PMID: 15044356 Review.
Cited by
-
Bi-directional drug-microbiome interactions of anti-diabetics.EBioMedicine. 2019 Jan;39:591-602. doi: 10.1016/j.ebiom.2018.11.046. Epub 2018 Dec 13. EBioMedicine. 2019. PMID: 30553752 Free PMC article. Review.
-
Gut hormone polyagonists for the treatment of type 2 diabetes.Peptides. 2018 Feb;100:190-201. doi: 10.1016/j.peptides.2017.12.021. Peptides. 2018. PMID: 29412819 Free PMC article. Review.
-
Intestinal hormones and growth factors: effects on the small intestine.World J Gastroenterol. 2009 Jan 28;15(4):385-406. doi: 10.3748/wjg.15.385. World J Gastroenterol. 2009. PMID: 19152442 Free PMC article. Review.
-
Spint1 disruption in mouse pancreas leads to glucose intolerance and impaired insulin production involving HEPSIN/MAFA.Nat Commun. 2024 Dec 3;15(1):10537. doi: 10.1038/s41467-024-54927-2. Nat Commun. 2024. PMID: 39627229 Free PMC article.
-
Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.Diabetes. 2011 Dec;60(12):3217-22. doi: 10.2337/db11-0101. Epub 2011 Oct 19. Diabetes. 2011. PMID: 22013015 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous